19
Indianapolis is poised to become a major hub for diabetes technology as Roche Diagnostics invests $550 million to expand its local facility for continuous glucose monitor (CGM) production. This significant investment promises to boost the availability of these life-changing devices, making continuous glucose monitoring more accessible to those managing diabetes. The expansion underscores Roche’s commitment to innovation in diabetes care solutions, and we’ll explore the impact this will have on the future of patient care.
Roche Diagnostics will build a $550 million expansion to produce continuous glucose monitors at an Indianapolis facility. Roche will use the site …
